Simplifying the energy balance message for breast cancer prevention

Cancer Prevention Research

Volumn 5, Issue 4, 2012, Pages 511-514

  Fabian, Carol J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; RALOXIFENE; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C; TAMOXIFEN;

ARTICLE; BODY MASS; BREAST CANCER; CANCER HORMONE THERAPY; CANCER PREVENTION; CANCER RISK; ENERGY BALANCE; ESTROGEN BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; OBESITY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); WEIGHT GAIN; BREAST TUMOR; FEMALE; NOTE; RISK;

BODY MASS INDEX; BREAST NEOPLASMS; FEMALE; HUMANS; RISK;

EID: 84864843447     PISSN: 19406207     EISSN: 19406215     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-12-0088     Document Type: Article

References (63)

1. Cecchini R, Costantino JP, Cauley JA, Cronin WM, Wickerham DL, Land SR, et al. Body mass index and the risk for developing invasive breast cancer among high risk women in NSABP P-1 and STAR breast cancer prevention trials. Cancer Prev Res 2012;5:583-92.
2. Vrieling A, Buck K, Kaaks R, Chang-Claude J. Adult weight gain in relation to breast cancer risk by estrogen and progesterone receptor status: a meta-analysis. Breast Cancer Res Treat 2010;123:641-9.
3. Decensi A, Robertson C, Guerrieri-Gonzaga A, Serrano D, Cazzaniga M, Mora S, et al. Randomized double-blind 2 x 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in high-risk premenopausal women. J Clin Oncol 2009;27:3749-56.
4. Bonanni B, Serrano D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Macis D, et al. Randomized biomarker trial of anastrozole or low-dose tamoxifen or their combination in subjects with breast intraepithelial neoplasia. Clin Cancer Res 2009;15:7053-60.
5. Gibney J, Johannsson G, Leung KC, Ho KK. Comparison of the metabolic effects of raloxifene and oral estrogen in postmenopausal and growth hormone-de ficient women. J Clin Endocrinol Metab 2005;90:3897-903. (Pubitemid 41058148)
6. Morimoto LM, White E, Chen Z, Chlebowski RT, Hays J, Kuller L, et al. Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control 2002;13:741-51. (Pubitemid 35204050)
7. Rose DP, Vona-Davis L. Interaction between menopausal status and obesity in affecting breast cancer risk. Maturitas 2010;66:33-8.
8. White KK, Park SY, Kolonel LN, Henderson BE, Wilkens LR. Body size and breast cancer risk: The multiethnic cohort. Int J Cancer. 2011 Nov 28. [Epub ahead of print].
9. Kuhl H. Breast cancer risk in the WHI study: the problem of obesity. Maturitas 2005;51:83-97. (Pubitemid 40692603)
10. Christodoulakos GE, Lambrinoudaki IV, Creatsa MG, Economou EV, Siasou Z, Panoulis CP, et al. Circulating levels of atherogenesis-associated adipocytokines and apoptotic markers are differentially influenced by hormone therapy, tibolone and raloxifene in healthy postmenopausal women. Climacteric 2008;11:155-65. (Pubitemid 351451118)
11. Johansson H, Gandini S, Guerrieri-Gonzaga A, Iodice S, Ruscica M, Bonanni B, et al. Effect of fenretinide and low-dose tamoxifen on insulin sensitivity in premenopausal women at high risk for breast cancer. Cancer Res 2008;68:9512-8.
12. Cohen I, Figer A, Tepper R, Shapira J, Altaras MM, Yigael D, et al. Ovarian overstimulation and cystic formation in premenopausal tamoxifen exposure: comparison between tamoxifen-treated and non-treated breast cancer patients. Gynecol Oncol 1999;72:202-7. (Pubitemid 29093776)
13. Manni A, Pearson OH. Antiestrogen-induced remissions in premenopausal women with stage IV breast cancer: effects on ovarian function. Cancer Treat Rep 1980;64:779-85. (Pubitemid 11199494)
14. Friedl A, Jordan VC, Pollak M. Suppression of serum insulin-like growth factor-1 levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993;29A:1368-72. (Pubitemid 23195373)
15. Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278:1407-11. (Pubitemid 27475968)
16. Lahmann PH, Schulz M, Hoffmann K, Boeing H, Tjønneland A, Olsen A, et al. Long-term weight change and breast cancer risk: the European prospective investigation into cancer and nutrition (EPIC). Br J Cancer 2005;93:582-9. (Pubitemid 43080003)
17. Harvie M, Howell A, Vierkant RA, Kumar N, Cerhan JR, Kelemen LE, et al. Association of gain and loss of weight before and after menopause with risk of postmenopausal breast cancer in the Iowa women's health study. Cancer Epidemiol Biomarkers Prev 2005; 14:656-61. (Pubitemid 40489211)
18. Ahn J, Schatzkin A, Lacey JV Jr, Albanes D, Ballard-Barbash R, Adams KF, et al. Adiposity, adult weight change, and postmenopausal breast cancer risk. Arch Intern Med 2007;167:2091-102. (Pubitemid 350036709)
19. Canchola AJ, Anton-Culver H, Bernstein L, Clarke CA, Henderson K, Ma H, et al. Body size and the risk of postmenopausal breast cancer subtypes in the California Teachers Study cohort. Cancer Causes Control. 2012 Jan 28. [Epub ahead of print].
20. Manders P, Pijpe A, Hooning MJ, Kluijt I, Vasen HF, Hoogerbrugge N, et al. Body weight and risk of breast cancer in BRCA1/2 mutation carriers. Breast Cancer Res Treat 2011;126:193-202.
21. Michels KB, Terry KL, Eliassen AH, Hankinson SE, Willett WC. Adult weight change and incidence of premenopausal breast cancer. Int J Cancer 2012;130:902-9.
22. Harvie M, Howell A. Energy balance adiposity and breast cancer- energy restriction strategies for breast cancerprevention. Obes Rev 2006;7:33-47.
23. Kaaks R, Van Noord PA, Den Tonkelaar I, Peeters PH, Riboli E, Grobbee DE. Breast cancer incidence in relation to height, weight and body fat distribution in the Dutch "DOM" cohort. Int J Cancer 1998;76:647-51. (Pubitemid 28243935)
24. Huang Z, Willett WC, Colditz GA, Hunter DJ, Manson JE, Rosner B, et al. Waist circumference, waist: hip ratio, and risk of breast cancer in the Nurses' Health Study. Am J Epidemiol 1999;150:1316-24.
25. Eichholzer M, Schmid SM, Bovey F, Jordan P, Rohrmann S, Huang DJ, et al. Impact of overweight and obesity on postmenopausal breast cancer: analysis of 20-year data from Switzerland. Arch Gynecol Obstet 2012;285:797-803.
26. Morris PG, Hudis CA, Giri D, Morrow M, Falcone DJ, Zhou XK, et al. Inflammation and increased aromatase expression occur in the breast tissue of obese women with breast cancer. Cancer Prev Res 2011;4:1021-9.
27. Endogenous Hormones and Breast Cancer Collaborative Group Key TJ, Appleby PN, Reeves GK, Roddam AW, Helzlsouer KJ, Alberg AJ, et al. Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies. Br J Cancer 2011;105:709-22.
28. Baer HJ, Tworoger SS, Hankinson SE, Willett WC. Body fatness at young ages and risk of breast cancer throughout life. Am J Epidemiol 2010;171:1183-94.
29. Sherman BM, Korenman SG. Measurement of serum LH,FSH, estradiol and progesterone in disorders of the human menstrual cycle: the inadequate luteal phase. J Clin Endocrinol Metab 1974;39:145-9.
30. Zain MM, Norman RJ. Impact of obesity on female fertility and fertility treatment. Womens Health (Lond Engl) 2008;4:183-94. (Pubitemid 351513638)
31. Terry KL, Willett WC, Rich-Edwards JW, Michels KB. A prospective study of infertility due to ovulatory disorders, ovulation induction, and incidence of breast cancer. Arch Intern Med 2006;166:2484-9. (Pubitemid 44913233)
32. Peacock SL, White E, Daling JR, Voigt LF, Malone KE. Relation between obesity and breast cancer in young women. Am J Epidemiol 1999;149:339-46. (Pubitemid 29302106)
33. Pichard C, Plu-Bureau G, Neves-E Castro M, Gompel A. Insulin resistance, obesity and breast cancer risk. Maturitas 2008;60:19-30.
34. Poole EM, Tworoger SS, Hankinson SE, Schernhammer ES, Pollak MN, Baer HJ. Body size in early life and adult levels of insulin-like growth factor 1 and insulin-like growth factor binding protein 3. Am J Epidemiol 2011;174:642-51.
35. Schernhammer ES, Holly JM, Pollak MN, Hankinson SE. Circulating levels of insulin-like growth factors, their binding proteins, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005;14:699-704. (Pubitemid 40489217)
36. Rollison DE, Newschaffer CJ, Tao Y, Pollak M, Helzlsouer KJ. Premenopausal levels of circulating insulin-like growth factor I and the risk of postmenopausal breast cancer. Int J Cancer 2006;118:1279-84. (Pubitemid 43185618)
37. Sieri S, Pala V, Brighenti F, Pellegrini N, Muti P, Micheli A, et al. Dietary glycemic index, glycemic load, and the risk of breast cancer in an Italian prospective cohort study. Am J Clin Nutr 2007;86:1160-6. (Pubitemid 47538322)
38. Del Giudice ME, Fantus IG, Ezzat S, McKeown-Eyssen G, Page D, Goodwin PJ. Insulin and related factors in premenopausal breast cancer risk. Breast Cancer Res Treat 1998;47:111-20. (Pubitemid 28046082)
39. Lipscombe LL, Goodwin PJ, Zinman B, McLaughlin JR, Hux JE. Diabetes mellitus and breast cancer: a retrospective population-based cohort study. Breast Cancer Res Treat 2006;98:349-56. (Pubitemid 44195606)
40. Chen J. Multiple signal pathways in obesity-associated cancer. Obes Rev 2011;12:1063-70.
41. De Angel RE, Conti CJ, Wheatley KE, Brenner AJ, Otto G, Degraffenried LA, et al. The enhancing effects of obesity on mammary tumor growth and Akt/mTOR pathway activation persist after weight loss and are reversed by RAD001. Mol Carcinog. 2012 Jan 30. [Epub ahead of print].
42. Crowe FL, Key TJ, Allen NE, Appleby PN, Overvad K, Grønbæk H, et al. A cross-sectional analysis of the associations between adult height, BMI and serum concentrations of IGF-I and IGFBP-1-2 and-3 in the European Prospective Investigation into Cancer and Nutrition (EPIC). Ann Hum Biol 2011;38:194-202.
43. Nogueira LM, Dunlap SM, Ford NA, Hursting SD. Calorie restriction and rapamycin inhibit MMTV-Wnt-1 mammary tumor growth in a mouse model of postmenopausal obesity. Endocr Relat Cancer 2012;19:57-68.
44. Subbaramaiah K, HoweLR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with infl ammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res 2011;4: 329-46.
45. Cleary MP, Ray A, Rogozina OP, Dogan S, Grossmann ME. Targeting the adiponectin:leptin ratio for postmenopausal breast cancer prevention. Front Biosci (Schol Ed) 2009;1:329-57.
46. Jardé T, Caldefie-Chézet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer 2009;16:1197-210.
47. Grossmann ME, Ray A, Dogan S, Mizuno NK, Cleary MP. Balance of adiponectin and leptin modulates breast cancer cell growth. Cell Res 2008;18:1154-6.
48. Grossmann ME, Ray A, Nkhata KJ, Malakhov DA, Rogozina OP, Dogan S, et al. Obesity and breast cancer: status of leptin and adiponectin in pathological processes. Cancer Metastasis Rev 2010;29:641-53.
49. Vona-Davis L, Rose DP. Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer 2007;14:189-206. (Pubitemid 47242622)
50. Macis D, Gandini S, Guerrieri-Gonzaga A, Johansson H, Magni P, Ruscica M, et al. Prognostic effect of circulating adiponectin in a randomized 2 x 2 trial of low-dose tamoxifen and fenretinide in premenopausal women at risk for breast cancer. J Clin Oncol 2012;30:151-7.
51. Bredella MA, Torriani M, Ghomi RH, Thomas BJ, Brick DJ, Gerweck AV, et al. Adiponectin is inversely associated with intramyocellular and intrahepatic lipids in obese premenopausal women. Obesity 2011;19:911-6.
52. Turer AT, Khera A, Ayers CR, Turer CB, Grundy SM, Vega GL, et al. Adipose tissue mass and location affect circulating adiponectin levels. Diabetologia 2011;54:2515-24.
53. Aguilar-Salinas CA, García EG, Robles L, Riaño D, Ruiz-Gomez DG, García-Ulloa AC, et al. High adiponectin concentrations are associated with the metabolically healthy obese phenotype. J Clin Endocrinol Metab 2008;93:4075-9.
54. Duggan C, Irwin ML, Xiao L, Henderson KD, Smith AW, Baumgartner RN, et al. Associations of insulin resistance and adiponectin with mortality in women with breast cancer. J Clin Oncol 2011;29:32-9.
55. Körner A, Pazaitou-Panayiotou K, Kelesidis T, Kelesidis I, Williams CJ, Kaprara A, et al. Total and high-molecular-weight adiponectin in breast cancer: in vitro and in vivo studies. J Clin Endocrinol Metab 2007;92:1041-8. (Pubitemid 46465681)
56. Eliassen AH, Colditz GA, Rosner B, Willett WC, Hankinson SE. Adult weight change and risk of postmenopausal breast cancer. JAMA 2006;296:193-201. (Pubitemid 44050373)
57. Madsen EL, Rissanen A, Bruun JM, Skogstrand K, Tonstad S, Hougaard DM, et al. Weight loss larger than 10% is needed for general improvement of levels of circulating adiponectin and markers of inflammation in obese subjects: a 3-year weight loss study. Eur J Endocrinol 2008;158:179-87. (Pubitemid 351298534)
58. Teras LR, Goodman M, Patel AV, Diver WR, Flanders WD, Feigelson HS. Weight loss and postmenopausal breast cancer in a prospective cohort of overweight and obese US women. Cancer Causes Control 2011;22:573-9.
59. Goss PE, Ingle JN, Alés-Martínez JE, Cheung AM, Chlebowski RT, Wactawski-Wende J, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 2011;364:2381-91.
60. Cuzick J, Forbes JF, Sestak I, Cawthorn S, Hamed H, Holli K, et al. Long-term results of tamoxifen prophylaxis for breast cancer-96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst 2007;99:272-82. (Pubitemid 47073490)
61. Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol 2001;8:580-5. (Pubitemid 32735038)
62. Land SR, Cronin WM, Wickerham DL, Costantino JP, Christian NJ, Klein WM, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the National Surgical Adjuvant Breast and Bowel Project P-1 Breast Cancer Prevention Trial. Cancer Prev Res 2011;4:1393-400.
63. Kushi LH, Doyle C, McCullough M, Rock CL, Demark-Wahnefried W, Bandera EV, et al. American Cancer Society Guidelines on nutrition and physical activity for cancer prevention: reducing the risk of cancer with healthy food choices and physical activity. CA Cancer J Clin 2012;62:30-67.